May. 24 at 11:05 PM
$BCTX BriaCell also collaborates with world-class partners, including the National Cancer Institute (NCI), part of the NIH, which is working with the company to further investigate its personalized, off-the-shelf platform. Recently, BriaCell announced a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. These collaborations highlight the scientific and clinical interest in BriaCell’s approach and strengthens its credibility in the competitive biotech landscape.
